Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jianjun Chen
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genovel Biotech Corp.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Genovel Biotech Corp. focuses on research and development for the medical and biotech fields. Its major aim is to attract investments in our projects to develop novel therapeutics for the treatment of cancer (especially acute myeloid leukemia [AML]). Dr. Chen is the Principal Investigator on the funded research grant that proposes to better understand the molecular mechanisms underlying AML pathogenesis, leukemia stem cell (LSC)/leukemia initiating cell (LIC) self-renewal and drug resistance, which may lead to the development of effective novel therapeutic strategies to treat AML. Given that the project aims of the grant, in part, are to investigate the roles and underlying mechanisms of METTL3 and METTL14, two proteins that compose N6-methyladenosine methyltransferase complex, in the development and maintenance of different major subtypes in AML and in the maintenance of LSC/LIC’s, as well as drug resistance/response and that the NIH-funded trial results could affect Dr. Chen’s interest in Genovel Biotech Corp., the interest was determined to be related.
The role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AML
Project Narrative: The major goal of this proposal is to investigate the roles and underlying mechanisms of METTL3 and METTL14, two proteins that compose N6-methyladenosine (m6A; a major type of modification in messenger RNA) methyltransferase (or called ?writer?) complex, in the development and maintenance of different major subtypes of acute myeloid leukemias (AMLs; one of the most common and fatal types of hematopoietic malignancies) and in the maintenance of the relevant leukemia stem/initiating cells (LSCs/LICs), as well as in drug resistance/response. Thus, the success of this project will provide profound novel insights into the biological functions and the underlying molecular mechanisms of m6A modification and the critical components of the m6A machinery (i.e., METTL3 and METTL14) in leukemia biology, which will shed new light on the molecular mechanisms underlying leukemia pathogenesis, LSC/LIC maintenance, and drug resistance/response, and may also lead to the development of effective novel therapeutic strategies to treat AMLs. Therefore, our project is of great significance in both basic research and translational research.
Filed on April 29, 2019.
Tell us what you know about Jianjun Chen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jianjun Chen”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jianjun Cheng | University of Illinois | Financial Disclosure | Royal Society of Chemistry for Journal of Biomaterials Science | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Soochow University | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Stocks/bonds/mutual funds | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Royal Society of Chemistry Journal of Biomaterials Science | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Dow Chemical Society | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Soochow University | |
| Jianjun Cheng | University of Illinois | Financial Disclosure | Royal Society of Chemistry |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.